Accession Number:

ADA612843

Title:

An Injectable Method for Posterior Lateral Spine Fusion

Descriptive Note:

Annual rept. 1 Sep 2012-31 Aug 2013

Corporate Author:

DUKE UNIV DURHAM NC

Personal Author(s):

Report Date:

2013-09-01

Pagination or Media Count:

8.0

Abstract:

The central hypothesis of this application is that posterolateral spine fusion can be successfully achieved with a novel and simple minimally invasive percutaneous injection. We propose that this can be done by injection of AdBMP2 transduced human fibroblasts possessing an icasp9M that have been micro-encapsulated with osteoclast degradable hydrogel into the desired fusion site. During this first year, we have nitiated the identification of the phenotype of the monocyte-like cells that appear to be capable of bone degradation. We have demonstrated in MSCs, which have a stably integrated icasp9M, can be rapidly induced to undergo apoptosis, after delivery of a chemical inducer of dimerization CID after encapsulation in PEG hydrogel. The next step is to start in vivo testing of this system. Additionally we have developed the methodology to noninvasively locate the hydrogel microsphere placement, optically, with respect to the newly forming bone. This has lead to a publication. We have also initiated studies to fuse the spine using our cell based gene therapy system encapsulated in the PEG hydrogel microspheres, in both mouse and rat. We will continue to complete these studies in the upcoming year.

Subject Categories:

  • Medicine and Medical Research

Distribution Statement:

APPROVED FOR PUBLIC RELEASE